Download PDF
Semin Respir Crit Care Med 2005; 26(5): 520-526
DOI: 10.1055/s-2005-922035
Copyright © 2005 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA.

Secondary Lung Tumors in Hematological Patients

Dino Amadori1 , Sonia Ronconi1
  • 1Division of Oncology and Diagnostics, Ospedale G. B. Morgagni, Forlì, Italy
Further Information

Publication History

Publication Date:
02 November 2005 (online)

    Permissions and Reprints

ABSTRACT

Advances made in the field of chemotherapy and radiotherapy have considerably increased the survival of patients with Hodgkin's disease (HD), non-Hodgkin's lymphoma (NHL), and chronic lymphocytic leukemia (CLL). Unfortunately, these antiblastic therapies have also increased the risk of late complications such as second tumors, especially second lung cancers. Although the role of ionizing radiations in carcinogenesis is now clear, less is known about the damage caused by chemotherapy, immunodeficiency induced by drugs or hematological pathologies, and cigarette smoking. In HD, the relative risk (RR) of second lung cancer increases considerably in relation to the dose of ionizing radiation given to the patient, with an RR of 9.6 when more than 9 Gy are administered. Some studies have reported a significantly higher risk of second lung cancers in smokers compared with nonsmokers (p = .03). The role of chemotherapy in the development of second lung cancers has yet to be determined. Although some authors correlate a greater risk with an increased number of chemotherapy cycles, others maintain that chemotherapy increases the risk of second lung cancer only if associated with cigarette smoking. Even less is known about the correlation between NHL and second lung cancer. Although the RR is higher in long-term NHL survivors than in healthy individuals (RR = 1.36), the heterogeneity of histotype and treatment does not permit us to confirm a correlation with chemotherapy and smoking. Conversely, in CLL, the development of second lung cancer appears to be linked to the immunodeficiency that accompanies this hematological malignancy. This is confirmed by the identical RR (1.66) for CLL patients subjected to chemotherapy and for those who have only follow-up.

KEYWORDS

Secondary lung cancer - Hodgkin's disease - non-Hodgkin's lymphoma - chronic lymphocytic leukemia

REFERENCES

  • 1 Heyssel R, Brill A B, Woodbury L A et al.. Leukemia in Hiroshima atomic bomb survivors.  Blood. 1960;  15 313-331
    PubMedGoogle Scholar
  • 2 Preston D L, Kusumi S, Tomonaga M et al.. Cancer incidence in atomic bomb survivors, III: Leukemia, lymphoma and multiple myeloma, 1950-1987.  Radiat Res. 1994;  137(Suppl 2) S68-S97
    PubMedGoogle Scholar
  • 3 Thompson D E, Mabuchi K, Ron E et al.. Cancer incidence in atomic bomb survivors, II: Solid tumors, 1958-1987.  Radiat Res. 1994;  137(Suppl 2) S17-S67
    CrossrefPubMedGoogle Scholar
  • 4 Tokunaga M, Land C E, Tokuoka S et al.. Incidence of female breast cancer among atomic bomb survivors, 1950-1985.  Radiat Res. 1994;  138 209-223
    PubMedGoogle Scholar
  • 5 Boice Jr J D. Cancerogenesis: a synopsis on human experience with external exposure in medicine.  Health Phys. 1988;  55 621-630
    PubMedGoogle Scholar
  • 6 Boice Jr J D, Land C E, Preston D L. Ionizing radiation. In: Schottenfeld D, Fraumeni JF Cancer epidemiology and prevention. New York; Oxford University Press 1996: 139-141
    Google Scholar
  • 7 Ponnaiya B, Cornforth M N, Ullrich R L. Radiation-induced chromosomal instability in BALB/c and C57BL/6 mice: the difference is as clear as black and white.  Radiat Res. 1997;  147 121-125
    PubMedGoogle Scholar
  • 8 National Research Council .Health Risk of Radon and Other Internally Deposited Alpha-Emitters. Washington, DC; National Academy Press 1998
    Google Scholar
  • 9 Moolgavkar S H, Luebeck E G, Krewski D, Zielinski J M. Radon, cigarette smoke, and lung cancer: a re-analysis of the Colorado Plateau uranium miners' data.  Epidemiology. 1993;  4 204-217
    PubMedGoogle Scholar
  • 10 Yao S X, Lubin J H, Qiao Y L et al.. Exposure to radon progeny, tobacco use and lung cancer in a case-control study in southern China.  Radiat Res. 1994;  138 326-336
    PubMedGoogle Scholar
  • 11 Kaldor J M, Day N E, Clarke E A et al.. Leukemia following Hodgkin's disease.  N Engl J Med. 1990;  322 7-13
    PubMedGoogle Scholar
  • 12 van Leeuwen F E, Klokman W J, Hagenbeek A et al.. Second cancer risk following Hodgkin's disease: a 20-year follow-up study.  J Clin Oncol. 1994;  12 312-325
    PubMedGoogle Scholar
  • 13 Kaldor J M, Day N E, Pettersson F et al.. Leukaemia following chemotherapy for ovarian cancer.  N Engl J Med. 1990;  322 1-6
    PubMedGoogle Scholar
  • 14 Curtis R, Boice Jr J D, Stovall M et al.. Risk of leukaemia after chemotherapy and radiation treatment for breast cancer.  N Engl J Med. 1992;  326 1745-1751
    PubMedGoogle Scholar
  • 15 Henry-Amar M. Second cancer after treatment for Hodgkin's disease: a report from the International database on Hodgkin's Disease.  Ann Oncol. 1992;  3(Suppl 4) S117-S128
    PubMedGoogle Scholar
  • 16 Kaldor J M, Day N E, Bell J et al.. Lung cancer following Hodgkin's disease: a case control study.  Int J Cancer. 1992;  52 677-681
    PubMedGoogle Scholar
  • 17 Tucker M A, Murray N, Shaw E G et al.. Second primary cancers related to smoking and treatment of small-cell lung cancer. Lung Cancer Working Cadre.  J Natl Cancer Inst. 1997;  89 1782-1788
    CrossrefPubMedGoogle Scholar
  • 18 van Leeuwen F E, Klokman W J, Veer M B et al.. Long-term risk of second malignancy in survivors of Hodgkin's disease treated during adolescence or young adulthood.  J Clin Oncol. 2000;  18 487-497
    PubMedGoogle Scholar
  • 19 Mauch P M, Kalish L A, Marcus K C et al.. Second malignancies after treatment for laparotomy staged IA-IIIB Hodgkin's disease: long-term analysis of risk factors and outcome.  Blood. 1996;  87 3625-3632
    PubMedGoogle Scholar
  • 20 Breslow N E, Takashima J R, Whitton J A, Moksness J, D'Angio G J, Green D M. Second malignant neoplasms following treatment for Wilms' tumor: a report from the National Wilms' Tumor Study Group.  J Clin Oncol. 1995;  13 1851-1859
    PubMedGoogle Scholar
  • 21 Relling M V, Rubnitz J E, Rivera G K et al.. High incidence of secondary brain tumours after radiotherapy and antimetabolites.  Lancet. 1999;  354 34-39
    CrossrefPubMedGoogle Scholar
  • 22 Birdwell S H, Hancock S L, Varghese A, Cox R S, Hoppe R T. Gastrointestinal cancer after treatment of Hodgkin's disease.  Int J Radiat Oncol Biol Phys. 1997;  37 67-73
    CrossrefPubMedGoogle Scholar
  • 23 Hoppe R T. Hodgkin's disease: complications of therapy and excess mortality.  Ann Oncol. 1997;  8(Suppl 1) S115-S118
    CrossrefPubMedGoogle Scholar
  • 24 Dores G M, Metayer C, Curtis R E et al.. Second malignant neoplasms among long-term survivors of Hodgkin's disease: a population-based evaluation over 25 years.  J Clin Oncol. 2002;  20 3484-3494
    CrossrefPubMedGoogle Scholar
  • 25 van Leeuwen F E, Klokman W J, Stovall M et al.. Roles of radiotherapy and smoking in lung cancer following Hodgkin's disease.  J Natl Cancer Inst. 1995;  87 1530-1537
    PubMedGoogle Scholar
  • 26 Travis L B, Gospodarowicz M, Curtis R E et al.. Lung cancer following chemotherapy and radiotherapy for Hodgkin's disease.  J Natl Cancer Inst. 2002;  94 182-192
    PubMedGoogle Scholar
  • 27 Swerdlow A J, Schoemaker M J, Allerton R et al.. Lung cancer after Hodgkin's disease: a nested case-control study of the relation treatment.  J Clin Oncol. 2001;  19 1610-1618
    PubMedGoogle Scholar
  • 28 Colvin O M. Antitumor alkylating agents. In: De Vita VT Jr, Hellman S, Rosenberg SA Cancer: Principles and Practice of Oncology. 6th ed. Philadelphia; Lippincott Williams & Wilkins 2001: 363-376
    Google Scholar
  • 29 Rudiger H W, Schwartz U, Serrand E et al.. Reduced O6-methylguanine repair in fibroblast cultures from patients with lung cancer.  Cancer Res. 1989;  49 5623-5626
    PubMedGoogle Scholar
  • 30 Kaur T B, Travaline J M, Gaughan J P, Richie Jr J P, Stellman S D, Lazarus P. Role of polymorphisms in codons 143 and 160 of the O6-alkylguanine DNA alkyltransferase gene in lung cancer risk.  Cancer Epidemiol Biomarkers Prev. 2000;  9 339-342
    PubMedGoogle Scholar
  • 31 Palmisano W A, Divine K K, Saccomanno G et al.. Predicting lung cancer by detecting aberrant promoter methylation in sputum.  Cancer Res. 2000;  60 5954-5958
    PubMedGoogle Scholar
  • 32 Hecht S S. Tobacco smoke carcinogens and lung cancer.  J Natl Cancer Inst. 1999;  91 1194-1210
    CrossrefPubMedGoogle Scholar
  • 33 Peterson L A, Liu X K, Hecht S S. Pyridyloxobutyl DNA adducts inhibit the repair of O6-methylguanine.  Cancer Res. 1993;  53 2780-2785
    PubMedGoogle Scholar
  • 34 Peters M V, Middlemiss K C. A study of Hodgkin's disease treated by irradiation.  Am J Roentgenol Radium Ther Nucl Med. 1958;  79 114-121
    PubMedGoogle Scholar
  • 35 Devita Jr V T, Serpick A A, Carbone P P. Combination chemotherapy in the treatment of advanced Hodgkin's disease.  Ann Intern Med. 1970;  73 881-895
    CrossrefPubMedGoogle Scholar
  • 36 Bonadonna G, Zucali R, Monfardini S, De Lena M, Uslenghi C. Combination chemotherapy of Hodgkin's disease with adriamycin, bleomycin, vinblastine and imidazole carboxamide versus MOPP.  Cancer. 1975;  36 252-259
    PubMedGoogle Scholar
  • 37 Diehl V, Mauch P M, Harris N L. Hodgkin's disease. In: De Vita VT Jr, Helleman S, Rosenberg SA Cancer: Principles and Practice of Oncology. 6th ed. Philadelphia; Lippincott Williams & Wilkins 2001: 2339-2387
    Google Scholar
  • 38 Ng A K, Mauch P M. Radiation therapy in Hodgkin's lymphoma.  Semin Hematol. 1999;  36 290-302
    PubMedGoogle Scholar
  • 39 Kaldor J M, Day N E, Band P et al.. Second malignancies following testicular cancer, ovarian cancer and Hodgkin's disease: an international collaborative study among cancer registries.  Int J Cancer. 1987;  39 571-585
    PubMedGoogle Scholar
  • 40 Swerdlow A J, Barber J A, Hudson G V et al.. Risk of second malignancy after Hodgkin's disease in a collaborative British cohort: the relation to age at treatment.  J Clin Oncol. 2000;  18 498-509
    PubMedGoogle Scholar
  • 41 Travis W D, Travis L B, Devesa S S. Lung cancer.  Cancer. 1995;  75(Suppl 1) S191-S202
    PubMedGoogle Scholar
  • 42 The International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma.  N Engl J Med. 1993;  329 987-994
    CrossrefPubMedGoogle Scholar
  • 43 Coiffier B, Lepage E, Briere J et al.. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large B-cell lymphoma.  N Engl J Med. 2002;  346 235-242
    CrossrefPubMedGoogle Scholar
  • 44 Zarrabi M H. Association of non-Hodgkin's lymphoma (NHL) and second neoplasms.  Semin Oncol. 1980;  7 340-341
    PubMedGoogle Scholar
  • 45 MacDougall B K, Weinerman B H, Kemel S. Second malignancies in non-Hodgkin's lymphoma.  Cancer. 1981;  48 1299-1301
    PubMedGoogle Scholar
  • 46 Travis L B, Curtis R E, Glimelius B et al.. Second cancers among long-term survivors of non-Hodgkin's lymphoma.  J Natl Cancer Inst. 1993;  85 1932-1937
    PubMedGoogle Scholar
  • 47 Andre M, Mounier N, Leleu X et al.. Second cancers and late toxicities after treatment of aggressive non-Hodgkin's lymphoma with the ACVBP regimen: a GELA cohort study on 2837 patients.  Blood. 2004;  103 1222-1228
    PubMedGoogle Scholar
  • 48 Travis L B, Curtis R E, Hankey B F, Fraumeni Jr J F. Second cancer in patients with chronic lymphocytic leukemia.  J Natl Cancer Inst. 1992;  84 1422-1427
    PubMedGoogle Scholar
  • 49 Hisada M, Biggar J, Green M H, Fraumeni Jr J F, Travis L B. Solid tumors after chronic lymphocytic leukemia.  Blood. 2001;  98 1979-1981
    CrossrefPubMedGoogle Scholar
  • 50 Linet M S, Cartwright R A. Leukaemia. In: Schottenfeld D, Fraumeni JF Jr Cancer Epidemiology and Prevention. 2nd ed. New York; Oxford University Press 1996: 841-892
    Google Scholar
  • 51 Robak T, Blonski J Z, Gora-Tybor J et al.. Second malignancies and Richter's syndrome in patients with chronic lymphocytic leukaemia treated with cladribine.  Eur J Cancer. 2004;  40 383-389
    CrossrefPubMedGoogle Scholar
  • 52 Cheson B D. Infections and immunosuppressive complications of purine analog therapy.  J Clin Oncol. 1995;  13 2431-2448
    PubMedGoogle Scholar
  • 53 Cheson B D, Vena D A, Barrett J, Freidlin B. Second malignancies as a consequence of nucleoside analog therapy for chronic lymphoid leukemias.  J Clin Oncol. 1999;  17 2454-2460
    PubMedGoogle Scholar
  • 54 Potti A, Ganti A K, Koch M, Mehdi S A, Levitt R. Identification of HER-2/neu overexpression and the clinical course of lung carcinoma in non-smokers with chronic lymphocytic leukemia.  Lung Cancer. 2001;  34 227-232
    CrossrefPubMedGoogle Scholar
  • 55 Stephens P, Hunter C, Bignell G et al.. Lung cancer: intragenic ERBB2 kinase mutations in tumours.  Nature. 2004;  431 525-526
    PubMedGoogle Scholar

Dino AmadoriM.D. 

Division of Oncology and Diagnostics, Ospedale G. B. Morgagni

Via C Forlanini 34, 47100 Forlì, Italy

Email: segronco@ausl.fo.it

      >